Concepedia

The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models

Ymera Pignochino, Carmine Dell’Aglio, Marco Basiricò, Federica Capozzi, Marco Soster, Serena Marchiò, Stefania Bruno, Loretta Gammaitoni, Dario Sangiolo, Erica Torchiaro,

Clinical Cancer Research · 2013 · 107 citations · 31 references

DOI

Abstract

mTORC2 activation is an escape mechanism from sorafenib treatment. When sorafenib is combined with everolimus, its antitumor activity is increased by complete inhibition of the mTOR pathway in the preclinical setting.

References

31

Culture of Human Endothelial Cells Derived from Umbilical Veins. IDENTIFICATION BY MORPHOLOGIC AND IMMUNOLOGIC CRITERIA

Eric Jaffe, Ralph L. Nachman, Carl G. Becker et al. · Journal of Clinical Investigation · 1973 · 6.9K citations · Full text

, , +17

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

Scott M. Wilhelm, Christopher Carter, LiYa Tang et al. · Cancer Research · 2004 · 4K citations · Full text

, , +12

Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton

Dos D. Sarbassov, Siraj M. Ali, Do‐Hyung Kim et al. · Current Biology · 2004 · 2.6K citations · Full text

, , +12

Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB

Dos D. Sarbassov, Siraj M. Ali, Shomit Sengupta et al. · Molecular Cell · 2006 · 2.6K citations · Full text

, , +4

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

Estela Jacinto, Robbie Loewith, Anja Schmidt et al. · Nature Cell Biology · 2004 · 2.1K citations

, , +10